Unicycive Therapeutics Inc recorded a cumulative net loss of $-35 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 275 other companies achieving higher income per employee. While Unicycive Therapeutics Inc's total ranking has deteriorated compared to the previous quarter from 3778 to 4062.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

UNCY Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,601,091	-1,815,864	-1,209,773	-1,252,182	-1,165,136
UNCY's Total Ranking	# 4062	# 3778	# 3574	#	#
Seq. Net Income Change	-	-	-	-	-

UNCY Company Profile >> Back to UNCY Efficiency Comparisons >> Compare UNCY Net Income per Employee to its Competitors

UNCY Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 276
Healthcare Sector	# 690
Overall Market	# 4062

Net Income per Employee Statistics
High	Average	Low
$ -50,000	$ -1,116,732	$ -1,815,864
(Jun 30 2021)		(Mar 31 2026)

News about Unicycive Therapeutics Inc Income per employee

Urgent Call to Action for Unicycive Therapeutics Investors Deadline Looms in Securities Fraud Case,

Unicycive Therapeutics Investors Urged to Act Amid Securities Fraud AllegationsIn recent developments, Rosen Law Firm, a prominent global investor rights law firm, is calling attention to potential securities fraud involving Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Investors who purchased securities of Unicycive Therapeutics between March 29, 2024, and June 27, 2025, should be aware of the imminent October 14, 2025 deadline for lead plaintiff motions. This marks a pivotal moment for stakeholders as they navigate the uncertainties surrounding their investments in the biotech firm.Unicycive Therapeutics, known for its innovative therapeutic solutions, has found itself in the spotlight due to recent financial concerns and allegations that could impact the integrity of its stock performance. The firm specializes in developing novel therapies aimed at addressing unmet medical needs, but questions about revenue generation from corporate clients have heightened scrutiny of its operations and financial disclosures. During the specified Class Period, Unicycive s reported revenue from corporate clients has been alarmingly low, contributing to worries among investors. These figures prompt a deeper investigation into the company s financial practices and the potential misrepresentation of its economic health. As a result, those affected by the alleged securities fraud face a crucial window to secure legal counsel. The Rosen Law Firm emphasizes the importance of taking proactive measures to safeguard one s investments.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-04T00:13:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.